Prediction and prevention of psychosis in youth at clinical high risk

Annual Review of Clinical Psychology

Volumn 8, Issue , 2012, Pages 269-289

  Addington, Jean ^a   Heinssen, Robert ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

psychosis; risk; schizophrenia; treatment

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; RISPERIDONE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITION; COGNITIVE THERAPY; DISEASE PREDISPOSITION; HIGH RISK POPULATION; HUMAN; JUVENILE; MENTAL HEALTH; MENTAL STRESS; PATIENT COUNSELING; PREDICTIVE VALUE; PREVENTION STUDY; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL INTERACTION; STRUCTURED INTERVIEW; TREATMENT PLANNING;

ADOLESCENT; HUMANS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84861495870     PISSN: 15485943     EISSN: 15485951     Source Type: Book Series    
DOI: 10.1146/annurev-clinpsy-032511-143146     Document Type: Review

References (108)

1. Addington J. 2007. The promise of early intervention. J. Early Interv. 1:294-307
2. Addington J, AddingtonD. 2005. Clinical trials during the prodromal stage of schizophrenia. Am. J. Psychiatry 162(7):1387
3. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, et al. 2007. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 33:665-72
4. Addington J, Cornblatt B, Cadenhead K, Cannon T, McGlashan T, et al. 2011a. At clinical high risk for psychosis: outcome for nonconverters. Am. J. Psychiatry 168:800-5
5. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. 2011b. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr. Res. 125:54-61
6. Addington J, Francey SM, Morrison AP. 2006. Working with People at High Risk of Developing Psychosis: A Treatment Handbook. Chichester, UK:Wiley
7. Addington J, Girard TA, Christensen BK, Addington D. 2010. Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders. J. Psychiatry Neurosci. 35(1):49-54
8. Addington J, Leriger E, Addington D. 2003. Symptom outcome one year after admission to an early psychosis program. Can. J. Psychiatry 48:204-7
9. Addington J, Penn D, Woods SW, Addington D, Perkins DO. 2008a. Facial affect recognition in individuals at clinical high risk for psychosis. Br. J. Psychiatry 192:67-68
10. Addington J, Penn D, Woods SW, Addington D, Perkins DO. 2008b. Social functioning in individuals at clinical high risk for psychosis. Schizophr. Res. 99(1-3):119-24
11. AmirN, Beard C, Taylor CT,KlumppH, Elias J, et al. 2009. Attention training in individuals with generalized social phobia: a randomized controlled trial. J. Consult. Clin. Psychol. 77(5):961-73
12. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, et al. 2010. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67(2):146-54
13. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Schlogelhofer M, et al. 2011. Emotion recognition in individuals at clinical high risk for schizophrenia. Schizophr. Bull. In press
14. An SK, Kang JI, Park JY, Kim KR, Lee SY, Lee E. 2010. Attribution bias in ultra-high risk for psychosis and first-episode schizophrenia. Schizophr. Res. 118(1-3):54-61
15. Ballon JS, Kaur T, Marks II, Cadenhead KS. 2007. Social functioning in young people at risk for schizophrenia. Psychiatry Res. 151(1-2):29-35
16. Beck AT, Rector NA. 2000. Cognitive therapy of schizophrenia: a new therapy for the new millennium. Am. J. Psychother. 54(3):291-300
17. Birchwood M, Smith J, MacMillan F, Hogg B, Prasad R, et al. 1989. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol. Med. 19:649-56
18. Borgwardt S,McGuire P, Fusar-Poli P. 2011. Gray matters!-Mapping the transition to psychosis. Schizophr. Res. 113:63-67
19. BradfordDW,Perkins DO, Lieberman JA. 2003. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs 63(21):2265-83
20. Brewer WJ,Wood SJ, Phillips LJ, Francey SM, Pantelis C, et al. 2006. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerabilitymarkers for psychosis. Schizophr. Bull. 32(3):538-55
21. Cadenhead KS. 2002. Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome. Psychiatr. Clin. North Am. 25(4):837-53
22. Cannon TD, Cadenhead K, CornblattB, WoodsSW,Addington J, et al. 2008. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65(1):28-37
23. Chung YS, Kang DH, Shin NY, Yoo SY, Kwon JS. 2008. Deficit of theory of mind in individuals at ultrahigh- risk for schizophrenia. Schizophr. Res. 99(1-3):111-18
24. Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, et al. 2007a. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr. Bull. 33(3):688-702
25. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, et al. 2007b. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry 68(4):546-57
26. Cornblatt BA, Obuchowski M. 1997. Update of high-risk research: 1987-1997. Int. Rev. Psychiatry 9:437-47
27. Eack SM,Greenwald DP,Hogarty SS, Cooley SJ,DiBarry AL, et al. 2009. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr. Serv. 60(11):1468-76
28. French P, Morrison AP. 2004. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis. London: Wiley
29. French P, Shryane N, Bentall RP, Lewis SW,Morrison AP. 2007. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. Br. J. Psychiatry Suppl. 51:s82-87
30. Fusar-Poli P,McGuire P, Borgwardt S. 2011. Mapping prodromal psychosis: a critical review of neuroimaging studies. Eur. Psychiatry. In press
31. Fusar-Poli P, Meneghelli A, Valmaggia L, Allen P, Galvan F, et al. 2009. Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. Br. J. Psychiatry 194(2):181-82
32. Genevsky A, Garrett CT, Alexander PP, Vinogradov S. 2010. Cognitive training in schizophrenia: a neuroscience-based approach. Dialogues Clin. Neurosci. 12(3):416-21
33. Gingerich S, Bellack A. 1995. Research-based family interventions for the treatment of schizophrenia. Clin. Psychol. 48:24-27
34. Gottesman I. 1991. Schizophrenia Genesis: The Origins of Madness. New York: Freeman
35. Green MF, Bearden CE,CannonTD, Fiske AP, Hellemann GS, et al. 2011. Social cognition in schizophrenia, part 1: performance across phase of illness. Schizophr. Bull. In press
36. Gross G. 1989. The "basic" symptoms of schizophrenia. Br. J. Psychiatry 155(Suppl. 7):21-25
37. Gumley AI, O'Grady M, McNay L, Reilly J, Power KG, Norrie J. 2003. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive-behavior therapy. Psychol. Med. 33:419-31
38. Hafner H, Loffler W, Maurer K, Hambrecht M, van der Heiden W. 1999. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr. Scand. 100:105-18
39. Haroun N, Dunn L, Haroun A, Cadenhead KS. 2006. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 32(1):166-78
40. Hawkins KA, Addington J, Keefe RSE, Christensen B, Perkins DO, et al. 2004. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr. Res. 67(2-3):115-22
41. Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, et al. 2008. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr. Res. 105(1-3):1-9
42. Jablensky A, Sartorius N, Ernberg G. 1992. Schizophrenia: manifestation, incidence, and course in different cultures. In A World Health Organization Ten-Country Study. Cambridge, UK: Cambridge Univ. Press
43. Karlsgodt KH, Sun D, Cannon T. 2010. Structural and functional brain abnormalities in schizophrenia. Curr. Dir. Psychol. Sci. 19:226-31
44. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, et al. 2006. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch. Gen. Psychiatry 63(3):250-58
45. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. 2001a. Diagnosing schizophrenia in the intial prodromal phase. Arch. Gen. Psychiatry 58:158-64
46. Klosterkötter J. Ruhrmann S. Schultze-Lutter F. Salokangas R.K. Linszen D. et al. 2005 The european prediction of psychosis study EPOS: Integrating early recognition and intervention in Europe World Psychiatry 4 3 161-167
47. Klosterkötter J, Schultze-Lutter F, Ruhrmann S. 2008. Kraepelin and psychotic prodromal conditions. Eur. Arch. Psychiatry Clin. Neurosci. 258(Suppl. 2):74-84
48. Klosterkötter J, Schultze-Lutter F, Wieneke A, Picker H, Steinmeyer EM. 2001b. Introduction and reliability of the first version of the Schizophrenia Prediction Instrument (SPI-A). Schizophr. Res. 49:2 (Abstr.
49. Lencz T, SmithCW,AutherA,Correll CU,CornblattB. 2004. Nonspecific and attenuated negative symptoms in patients at clinical high risk for schizophrenia. Schizophr. Res. 68(1):37-48
50. LewisD, Lieberman J. 2000. Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-34
51. Lewis SW, Tarrier N, HaddockG, Bentall R, Kinderman P, et al. 2002. Cognitive therapy improves 18-month outcomes but not time to relapse in first-episode schizophrenia. Schizophr. Res. 53:14
52. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. 2004. Risk factors for transition to first episode psychosis among individuals with "at-risk mental states." Schizophr. Res. 71(2-3):227-37
53. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, et al. 2006. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163(5):790-99
54. McGorry PD, Nelson B, Goldstone S, Yung AR. 2010. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can. J. Psychiatry 55(8):486-97
55. McGorry PD, Purcell R, Goldstone S, Amminger GP. 2011. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr. Opin. Psychiatry 24(4):301-6
56. McGorry PD, Singh BS. 1995. Schizophrenia: risk and possibility of prevention. In Handbook of Studies on Preventive Psychiatry, ed. B Raphael, GD Burrows, 27:491-514. Oxford, UK: Elsevier Sci.
57. McGorry PD, Yung A, Phillips L, YuenH, Francey S, et al. 2002. Randomized controlled trial of interventions designed to reduce risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 59:921-28
58. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, et al. 2003. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 29(4):703-15
59. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, et al. 2002. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 159:863-65
60. Morrison AP. 2001. The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behav. Cogn. Psychother. 29:257-76
61. Morrison AP, Bentall R, French P, Kilcommons A, Green J, et al. 2003. Cognitive therapy in ultra high risk individuals for psychosis: randomised controlled trial. Schizophr. Res. 60:326 (Abstr.
62. Morrison AP, French P, Parker S, RobertsM, Stevens H, et al. 2007a. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 33(3):682-87
63. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, et al. 2004a. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185:291-97
64. MorrisonAP, French P, Wells A. 2007b. Metacognitive beliefs across the continuum of psychosis: comparisons between patients with psychotic disorders, patients at ultra-high risk and non-patients. Behav. Res. Ther. 45(9):2241-46
65. Morrison AP, Renton JC, Williams S, Dunn H, Knight A, et al. 2004b. Delivering cognitive therapy to people with psychosis in a community mental health setting: an effectiveness study. Acta Psychiatr. Scand. 110(1):36-44
66. Nelson B, Yuen K, Yung AR. 2011. Ultra high risk (UHR) for psychosis criteria: Are there different levels of risk for transition to psychosis? Schizophr. Res. 125(1):62-68
67. Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, et al. 2006. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr. Res. 84(1):100-11
68. Niendam TA, Bearden CE, Zinberg J, Johnson JK, O'Brien M, Cannon TD. 2007. The course of neurocognition and social functioning in individuals at ultra high risk for psychosis. Schizophr. Bull. 33(3):772-81
69. O'BrienM, Zinberg J, Bearden CE, DaleyM, Niendam T, et al. 2007. Psychoeducational multi-family group treatment with adolescents at high risk for developing psychosis. Early Interv. Psychiatry 1:325-32
70. O'Brien MP, Zinberg JL, Ho L, Rudd A, Kopelowicz A, et al. 2009. Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: a longitudinal study. Schizophr. Res. 107(2-3):198-205
71. Pantelis C, Yucel M, Bora E, Fornito A, Testa R, et al. 2009. Neurobiological markers of illness onset in psychosis and schizophrenia: the search for a moving target. Neuropsychol. Rev. 19(3):385-98
72. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. 2005. Psychosocial treatment for firstepisode psychosis: a research update. Am. J. Psychiatry 162(12):2220-32
73. Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, et al. 2009. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust. N. Z. J. Psychiatry 43(9):818-29
74. Pilling S, Bebbington P,Kuipers E, Garety P, Geddes J, et al. 2002. Psychological treatments in schizophrenia: I. Meta-analyses of family intervention and cognitive behavior therapy. Psychol. Med. 32:763-82
75. Preti A, Cella M. 2010. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 123(1):30-36
76. Roberts G. 1991. Delusional belief system and meaning in life: a preferred reality. Br. J. Psychiatry 158:19-28
77. Ruhrmann S, Schultze-Lutter F, Salokangas RK,HeinimaaM, Linszen D, et al. 2010. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 67(3):241-51
78. Schaffner KF, McGorry PD. 2001. Preventing severe mental illnesses-new prospects and ethical challenges. Schizophr. Res. 51:3-15
79. Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, et al. 2011. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis.
80. Schizophr. Bull. In press Schultze-Lutter F. 2009. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr. Bull. 35(1):5-8
81. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. 2007a. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome: Giovanni Fioriti
82. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer EM, Ruhrmann S. 2007b. Predicting first-episode psychosis by basic symptom criteria. Clin. Neuropsychiatry 4(1):11-22
83. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J. 2010. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr. Bull. 36(1):182-91
84. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. 2008. Early detection and early intervention in psychosis in Western Europe. Clin. Neuropsychiatry 5(6):303-15
85. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, et al. 2010. Neuropsychology of the prodrome to psychosis in theNAPLS consortium: relationship to family history and conversion to psychosis. Arch. Gen. Psychiatry 67(6):578-88
86. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, et al. 2000. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry 57:165-72
87. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, et al. 2010. Neuroimaging predictors of transition to psychosis-a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 34(8):1207-22
88. Tarrier N, Yusopoff L, Kinney C, McCarthy E, Gledhill A, et al. 1998. Randomized controlled trial of intensive cognitive behavior therapy for patients with chronic schizophrenia. Br. Med. J. 317:303-7
89. Thompson KN, Berger G, Phillips LJ, Komesaroff P, Purcell R, McGorry PD. 2007. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J. Psychiatr. Res. 41(5):446-50
90. vanOs J, Bak M, HanssenM, BijlRV, de Graaf R, Verdoux H. 2002. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156(4):319-27
91. Van Rijn S, Schothorst P, Wout MV, SprongM, Ziermans T, et al. 2010. Affective dysfunctions in adolescents at risk for psychosis: emotion awareness and social functioning. Psychiatry Res. 187(1-2):100-5
92. Velthorst E, Nieman DH, Linszen D, Becker H, de HL, et al. 2010. Disability in people clinically at high risk of psychosis. Br. J. Psychiatry 197(4):278-84
93. Walker EF,Cornblatt BA, Addington J,Cadenhead KS,CannonTD, et al. 2009. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res. 115(1):50-57
94. Weiser M. 2011. Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase. Am. J. Psychiatry 168(8):761-63
95. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, et al. 2009. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 35(5):894-908
96. Woods SW, Walsh BC, Pearlson GD, McGlashan TH. 2006. The glycine treatment of prodromal symptoms. Schizophr. Res. 86:s7 (Abstr.
97. Yung AR, Buckby JA, Cosgrave EM, Killackey EJ, Baker K, et al. 2007a. Association between psychotic experiences and depression in a clinical sample over 6 months. Schizophr. Res. 91(1-3):246-53
98. Yung AR, McGorry PD. 1996a. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust. N. Z. J. Psychiatry 30:587-99
99. Yung AR, McGorry PD. 1996b. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22(2):353-70
100. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. 1996. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 22(2):283-303
101. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, et al. 2008. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr. Res. 105(1-3):10-17
102. Yung AR, Nelson B, Thompson A, Wood SJ. 2010. The psychosis threshold in ultra high risk (prodromal) research: Is it valid? Schizophr. Res. 120(1-3):1-6
103. Yung AR, Phillips LJ, McGorry P, Hallgreen MA, McFarlane CA, et al. 1998. Can we predict the onset of first-episode psychosis in a high-risk group? Int. Clin. Psychopharmacol. 13(1):S23-30
104. Yung AR, Phillips LJ, Nelson B, Francey SM, PanyuenH, et al. 2011. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J. Clin. Psychiatry 72(4):430-40
105. Yung AR, Phillips LJ, Yuen H, Francey S, McFarlane CA, et al. 2003. Psychosis prediction: a 12-month follow-up of a high-risk ("prodromal" ) group. Schizophr. Res. 60:21-32
106. Yung AR, Phillips LJ, Yuen HP, McGorry PD. 2004. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 67(2-3):131-42
107. Yung AR, Yuen HP, Berger G, Francey S, Hung TC, et al. 2007b. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr. Bull. 33:673-81
108. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, et al. 2005. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 39(11-12):964-71